The following rewritten from UVM tests/05components/50in_order/20int gives a false Verilation error: %Error: t/t_0.v:16:43: Reference to 'T' type would form a ...

Of the litany of early, shameful lessons marked on the map of the soul, there are few as damning and intense as early crushes. Immense feelings that emerge from unknown corners of the heart to steer ...

Thinking of the screen as skin means rethinking the relationship between body and technology. In Emanuela Moretti’s ...

The Weekly Notable Startup Funding Report takes us on a trip across various ecosystems in the US, highlighting some of the notable funding activity in the various markets that we track. The notable ...

Just when investors were thinking they understood the AI Boom, the rules shifted again… Forget everything you thought you knew about the “Magnificent 7.” We’ve moved beyond the individual gladiators ...

Abstract: The recursive median filter has stronger noise at-tenuation capability than the median filter, especially for high-intensity and irregularly distributed noise. However, the recursive ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...